Swedish Orphan Biovitrum AB (SOBI):企業の財務・戦略的SWOT分析

◆英語タイトル:Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH62106FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Swedish Orphan Biovitrum AB (SOBI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Swedish Orphan Biovitrum AB (Sobi), formerly known as Biovitrum AB, is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, immunology, speciality care, inflammation and genetic and metabolic diseases. Sobi also manufactures and markets specialty and rare disease products for partner companies. The company has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

Apr 26,2021: Invitation – Presentation of Sobi’s Q1 2021 results
Feb 18,2021: Sobi publishes report for the fourth quarter and full-year 2020
Feb 03,2021: Invitation – Presentation of Sobi”s Q4 and FY 2020 results
Dec 21,2020: Sobi appoints new Head of North America ahead of launch phase
Oct 22,2020: Sobi publishes report for the third quarter 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Swedish Orphan Biovitrum AB – Key Facts
Swedish Orphan Biovitrum AB – Key Employees
Swedish Orphan Biovitrum AB – Key Employee Biographies
Swedish Orphan Biovitrum AB – Major Products and Services
Swedish Orphan Biovitrum AB – History
Swedish Orphan Biovitrum AB – Company Statement
Swedish Orphan Biovitrum AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Swedish Orphan Biovitrum AB – Business Description
Product Category: Haematology
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Specialty Care
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other
Performance
Overview
Geographical Segment: Rest of the World
Performance
Swedish Orphan Biovitrum AB – Corporate Strategy
Swedish Orphan Biovitrum AB – SWOT Analysis
SWOT Analysis – Overview
Swedish Orphan Biovitrum AB – Strengths
Swedish Orphan Biovitrum AB – Weaknesses
Swedish Orphan Biovitrum AB – Opportunities
Swedish Orphan Biovitrum AB – Threats
Swedish Orphan Biovitrum AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Swedish Orphan Biovitrum AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 26, 2021: Invitation – Presentation of Sobi’s Q1 2021 results
Feb 18, 2021: Sobi publishes report for the fourth quarter and full-year 2020
Feb 03, 2021: Invitation – Presentation of Sobi”s Q4 and FY 2020 results
Dec 21, 2020: Sobi appoints new Head of North America ahead of launch phase
Oct 22, 2020: Sobi publishes report for the third quarter 2020
Aug 18, 2020: Sobi appoints Dr Ravi Rao as new Head of Research & Development
Jul 16, 2020: Sobi publishes report for the second quarter 2020
Apr 29, 2020: Sobi publishes report for the first quarter 2020
Apr 17, 2020: Sobi releases new haemophilia treatment report
Apr 13, 2020: Sobi sees strong revenue and EBITA growth in the first quarter 2020
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Swedish Orphan Biovitrum AB, Key Facts
Swedish Orphan Biovitrum AB, Key Employees
Swedish Orphan Biovitrum AB, Key Employee Biographies
Swedish Orphan Biovitrum AB, Major Products and Services
Swedish Orphan Biovitrum AB, History
Swedish Orphan Biovitrum AB, Subsidiaries
Swedish Orphan Biovitrum AB, Key Competitors
Swedish Orphan Biovitrum AB, Ratios based on current share price
Swedish Orphan Biovitrum AB, Annual Ratios
Swedish Orphan Biovitrum AB, Annual Ratios (Cont...1)
Swedish Orphan Biovitrum AB, Annual Ratios (Cont...2)
Swedish Orphan Biovitrum AB, Interim Ratios
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Swedish Orphan Biovitrum AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Swedish Orphan Biovitrum AB (SOBI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AiVita Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AiVita Biomedical Inc (AiVita) is a biotechnology company developing novel stem cell technologies to develop cell-based treatments and healthcare products for the treatment of cancer, vision loss, and skincare formulations. Its lead therapeutic candidate is a patient-specific immunotherapy f …
  • Wiener Osiguranje Vienna Insurance Group d.d.:企業の戦略的SWOT分析
    Wiener Osiguranje Vienna Insurance Group d.d. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Laboratorios SALVAT SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorios SALVAT SA (SALVAT) is a pharmaceutical company with focus on the development and commercialization of innovative medicines. The company manufactures drugs in various segments such as personal healthcare, digestive / metabolism, urological conditions, ophthalmological diseases, E …
  • French National Institute of Health and Medical Research:医療機器:M&Aディール及び事業提携情報
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • Hess Corp (HES):企業の財務・戦略的SWOT分析
    Hess Corp (HES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Suda Ltd (SUD)-製薬・医療分野:企業M&A・提携分析
    Summary Suda Ltd (Suda) is a drug delivery company that offers oro-mucosal administration solutions. The company’s products include artimist, zolpimist, SUD-001, SUD-002, SUD-003, SUD-004 and SUD-005. Its artimist is a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria. S …
  • IMAX Corporation:企業のM&A・事業提携・投資動向
    IMAX Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IMAX Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Patterson Companies, Inc.
    Patterson Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Patterson Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • LeasePlan Corporation N.V.:企業の戦略・SWOT・財務情報
    LeasePlan Corporation N.V. - Strategy, SWOT and Corporate Finance Report Summary LeasePlan Corporation N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Arabian Bemco Contracting Co. Ltd.:企業の戦略・SWOT・財務分析
    Arabian Bemco Contracting Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Arabian Bemco Contracting Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Unchained Labs:製薬・医療:M&Aディール及び事業提携情報
    Summary Unchained Labs (Unchained) is a life science tools company which offers protein stability assessment products for biologics. Its product portfolio includes UNcle (biologics stability platform), HUNK (aggregation predictor), pUNk (protein sizing system), GRUNT (automated formulation preparati …
  • Anglo American South Africa Limited:企業の戦略・SWOT・財務情報
    Anglo American South Africa Limited - Strategy, SWOT and Corporate Finance Report Summary Anglo American South Africa Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Aromatech SAS:企業の戦略・SWOT・財務情報
    Aromatech SAS - Strategy, SWOT and Corporate Finance Report Summary Aromatech SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Astellas Pharma Inc.:企業の戦略・SWOT・財務情報
    Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report Summary Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Grupo Biotoscana SL (GBIO33):製薬・医療:M&Aディール及び事業提携情報
    Summary Grupo Biotoscana SL (Biotoscana) is a biopharmaceutical company that develops, manufactures and markets advanced medicines for unmet medical needs. The company offers products such as vidaza, ladevina, zyvalix, mielozitidina, votrynib, bozob, timab, enzastar, capebina, leprid, olvestran, toc …
  • China Railway Signal & Communication Corp Ltd:企業の戦略・SWOT・財務情報
    China Railway Signal & Communication Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary China Railway Signal & Communication Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Green Dot Corporation
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • China Gas Holdings Ltd (384):電力:M&Aディール及び事業提携情報
    Summary China Gas Holdings Ltd (CGHL) is a gas operator and service provider. The company offers piped natural gas, compressed natural gas, liquid petroleum gas and liquefied natural gas. Its activities include construction and operation of gas stations, gas pipeline infrastructure facilities, gas t …
  • Sanmina Corporation (SANM):企業の財務・戦略的SWOT分析
    Sanmina Corporation (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Bhansali Engineering Polymers Ltd (BEPL):企業の財務・戦略的SWOT分析
    Summary Bhansali Engineering Polymers Ltd (BEPL), formerly Bhansali Steel Ltd is a petrochemical company that manufactures and markets acrylonitrile butadiene styrene. The company's products include general ABS, extrusion ABS, flame retardant ABS, ABS-GF or SAN-GF, PMMA-ABS, PVC modifier, PC or ABS …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆